Four things to know:
1. The patients participated in CartiHeal’s FDA investigational device exemption randomized and controlled study, which seeks to show superiority of the Agili-C implant over the current standard of care — microfracture and debridement.
2. The Agili-C implant is designed to help patients with knee-cartilage defects to regenerate their own healthy cartilage and its underlying subchondral bone.
3. The cell-free implant is CE marked for use in cartilage and osteochondral defects and was implanted in over 400 patients with knee, ankle and toe cartilage lesions in a series of trials in Europe and Israel. Agili-C is not yet available for sale in the U.S.
4. Dr. Hacker is one of 15 principal investigators in the U.S. participating in the study. He is board-certified and fellowship-trained in knee and shoulder surgery in the treatment of sports related injuries and is the current orthopedic surgeon for the United States Olympic Team.
More articles on biologics:
BioBridge adds orthopedic surgeon to regenerative medicine advisory board
Misonix acquires Solys Medical for $97M — 5 Takeaways
UNC, NC State scientists collaborate to print human body tissues
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
